Peptide therapy TikTok claims: separating signal from hype

What did @drmichaelsays actually say?

The creator introduced retatrutide, which they call "the Triple G," as a weight loss drug currently in phase three trials and "not licensed yet." They claimed it targets three hormones, GLP-1, GIP, and glucagon, compared to one or two for existing drugs. They argued the glucagon component specifically helps "the liver to break down stored fats" and reduces visceral fat and liver fat. They also explained that glucagon alone would raise blood sugar, but the GLP-1 and GIP components act as "a buffer" to keep glucose stable. They predicted availability in 2026 and called it a potential "game changer."

Credit where it is due: the creator was upfront that this is not medical advice and the drug is not yet approved. That kind of disclaimer is rare in TikTok peptide content, and it matters.

Does the science back this up?

Mostly, yes. The mechanistic claims about retatrutide are grounded in real trial data, though some of the framing oversimplifies what the glucagon agonism actually does.

Retatrutide is a single-molecule tri-agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors. The phase two trial published by Jastreboff et al. in 2023 in the New England Journal of Medicine showed participants lost up to 24.2 percent of body weight at 48 weeks, which exceeds tirzepatide's published figures. The visceral fat reduction claim is supported by that same trial, which measured significant reductions in liver fat content using MRI-PDFF assessments. So the creator is not making things up here.

The glucagon mechanism claim is also broadly accurate. Glucagon receptor agonism does increase hepatic fat oxidation and energy expenditure, which is the theoretical basis for why a tri-agonist might outperform dual agonists on fat loss. The phase three TRIUMPH program is ongoing as of early 2025.

What did they get wrong (or right)?

The creator got the core science largely right, but the glucagon explanation is a bit loose. Saying glucagon "helps the liver to break down stored fats" is a simplification. Glucagon receptor agonism primarily increases hepatic glucose output and fat oxidation, but calling it a straightforward fat-breakdown mechanism glosses over the metabolic complexity involved.

The bigger issue is the blood sugar framing. The creator said GLP-1 and GIP act as a "buffer" keeping glucose stable when glucagon is active. That is a reasonable lay explanation of the counter-regulatory balance, but it implies a cleaner equilibrium than the data shows. Early retatrutide trials did observe nausea, vomiting, and some metabolic variability. The safety profile at high doses is still being established in the phase three program.

The 2026 availability prediction is speculative. Phase three trials were still enrolling and running in 2024, and regulatory review timelines at the FDA are not guaranteed. Saying it "will be here in 2026" treats a reasonable estimate as a certainty, which is not fair to viewers making decisions based on this content.

• Got right: tri-agonist mechanism, visceral fat reduction data, glucagon-glucose tension
• Got loose: glucagon as a simple fat-breakdown switch, 2026 as a firm date

What should you actually know?

Retatrutide is a real, legitimately interesting drug candidate, but it does not exist in approved form anywhere as of early 2025. That means there is no regulated, licensed version you can obtain. Compounded versions or research chemical versions claiming to be retatrutide have no verified quality control or confirmed safety data.

The phase two results from Jastreboff et al. (2023, NEJM) are genuinely striking, but phase two trials are not the finish line. Drugs fail in phase three for reasons that phase two data does not predict, including longer-term safety signals, rare adverse events, and regulatory scrutiny of manufacturing standards.

If you have fatty liver disease or metabolic syndrome, there are already approved therapies and lifestyle interventions with established evidence. Waiting on an unlicensed drug based on a TikTok prediction timeline is not a clinical strategy. Talk to a physician who can assess your specific situation with tools that exist right now.

The NASH or MASLD angle the creator raises is worth taking seriously. Liver fat reduction is one of the areas where retatrutide data looks most promising, and it is an area of genuine unmet clinical need. But that is precisely why this drug deserves careful phase three scrutiny rather than hype-driven predictions.